Regulus Therapeutics Stock Forecast, Price & News

-0.05 (-4.82 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume6.49 million shs
Average Volume3.16 million shs
Market Capitalization$74.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Regulus Therapeutics logo

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.40 out of 5 stars

Medical Sector

730th out of 2,100 stocks

Pharmaceutical Preparations Industry

361st out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

Is Regulus Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regulus Therapeutics stock.
View analyst ratings for Regulus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Regulus Therapeutics?

Wall Street analysts have given Regulus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regulus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Regulus Therapeutics

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.01.
View Regulus Therapeutics' earnings history

How has Regulus Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Regulus Therapeutics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGLS shares have increased by 64.6% and is now trading at $0.9877.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RGLS?

2 brokerages have issued twelve-month price objectives for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $2.00. On average, they expect Regulus Therapeutics' share price to reach $1.50 in the next year. This suggests a possible upside of 51.9% from the stock's current price.
View analysts' price targets for Regulus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the following people:
  • Mr. Joseph P. Hagan M.B.A., Pres, CEO & Director (Age 52, Pay $826.08k)
  • Ms. Crispina Calsada, Chief Financial Officer (Age 51, Pay $456.65k)
  • Mr. Christopher Ray Aker J.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 60, Pay $457.47k)
  • Mr. Daniel J. Penksa, Controller & Principal Accounting Officer (Age 35)
  • Dr. Denis Drygin Ph.D., Chief Scientific Officer (Age 47)
  • Mr. Turner Jenkins, Sr. Director of Corp. Devel.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics CEO Joseph Hagan on Joseph Hagan has an approval rating of 49% among Regulus Therapeutics' employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Regulus Therapeutics' key competitors?

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Endurant Capital Management LP (3.17%), Victory Capital Management Inc. (2.98%), Asymmetry Capital Management L.P. (2.65%), Ikarian Capital LLC (1.66%), Acadian Asset Management LLC (0.62%) and Geode Capital Management LLC (0.51%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Daniel R Chevallard, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends for Regulus Therapeutics

Which major investors are selling Regulus Therapeutics stock?

RGLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Regulus Therapeutics company stock in the last year include Christopher Ray Aker, and Joseph P Hagan.
View insider buying and selling activity for Regulus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Regulus Therapeutics stock?

RGLS stock was purchased by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, Asymmetry Capital Management L.P., Victory Capital Management Inc., Ikarian Capital LLC, Acadian Asset Management LLC, Atom Investors LP, Geode Capital Management LLC, and Morgan Stanley.
View insider buying and selling activity for Regulus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.99.

How much money does Regulus Therapeutics make?

Regulus Therapeutics has a market capitalization of $74.00 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Regulus Therapeutics have?

Regulus Therapeutics employs 23 workers across the globe.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is

Where are Regulus Therapeutics' headquarters?

Regulus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.